undamentalytics Newsletter
Sign in

Korsana Biosciences, Inc. income statement

In fiscal 2025, Korsana Biosciences, Inc. reported revenue of $2.1m, up 3.7% on the year before, operating income of −$5.0m (a -239.8% margin) and net income of −$3.5m, or −$1.11 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue52400222
Research and development95563862012
General and administrative342921138567
Operating income−125−81−55−19−13−4−5−7
Income before tax−122−122−52−44−5−3−4—
Income tax0000000—
Net income−123−78−52−44−5−3−4−7
Diluted EPS−$89.80−$2.56−$1.32−$20.28−$2.25−$1.21−$1.11−$1.72
Diluted shares (average)1m2m2m2m2m3m3m4m
EBITDA−122−79−55−18−13———

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KRSA vs MCRBKRSA vs OVIDABSI vs KRSACLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korsana Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korsana Biosciences, Inc.